Key result
Fetal aortic valvuloplasty is a fetal cardiac intervention that may be performed to prevent progression to hypoplastic left heart syndrome in utero.
Why the study?
Advances in fetal echocardiography have enabled fetal cardiac intervention, such as fetal aortic valvuloplasty, to prevent progression to hypoplastic left heart syndrome in utero.
Fetal aortic valvuloplasty is a fetal cardiac intervention that may prevent the progression of select congenital heart defects to hypoplastic left heart syndrome in utero.
Answers are grounded in this paper and cite their sources.
May offer intervention option for select fetal aortic stenosis; leaves open need for prospective trials before clinical adoption.
Advances in fetal echocardiography have allowed for the prenatal diagnosis of congenital heart disease and an understanding of its natural history in utero. This insight has led to the development of fetal cardiac intervention (FCI) for select defects to prevent significant morbidity or mortality postnatally. Fetal aortic valvuloplasty (FAV) may be performed to prevent progression to hypoplastic left heart syndrome, a severe form of congenital heart disease, in utero. The current review focuses on this type of FCI and discusses the history of FAV, the rationale for intervention, candidate selection, procedural technique, and outcomes to date. Finally, the importance of building a multidisciplinary team to perform FCI is addressed.
No takes yet. Share an insight, caveat, or question.
Crystal et al. (2019) conducted a review in Hypoplastic left heart syndrome. Fetal aortic valvuloplasty was evaluated. Fetal aortic valvuloplasty is a fetal cardiac intervention that may be performed to prevent progression to hypoplastic left heart syndrome in utero.
Synapse has enriched 10 related papers. Consider them for comparative context: